These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 8748625)

  • 1. Dopaminergic agonists in the treatment of Parkinson's disease: a review.
    Piccoli F; Riuggeri RM
    J Neural Transm Suppl; 1995; 45():187-95. PubMed ID: 8748625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?
    Mercuri NB; Bernardi G
    Trends Pharmacol Sci; 2005 Jul; 26(7):341-4. PubMed ID: 15936832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved therapies for Parkinson's disease: life beyond dopamine D2/D3 receptor agonists.
    Williams M; Wright S; Lloyd GK
    Trends Pharmacol Sci; 1997 Sep; 18(9):307-10. PubMed ID: 9345846
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment strategies in Parkinson's disease after a quarter century experiences with L-DOPA therapy.
    Fischer PA
    J Neural Transm Suppl; 1995; 46():381-9. PubMed ID: 8821073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopaminergic drugs in development for Parkinson's disease.
    Korczyn AD
    Adv Neurol; 2003; 91():267-71. PubMed ID: 12442685
    [No Abstract]   [Full Text] [Related]  

  • 6. [Controversial issues concerning the initial treatment of Parkinson's disease: L-Dopa or dopaminergic agonists?].
    Defer GL
    Rev Neurol (Paris); 1999 Jan; 155(1):43-5. PubMed ID: 10093847
    [No Abstract]   [Full Text] [Related]  

  • 7. [Medicinal treatment of idiopathic Parkinson's disease].
    Klockgether T
    Nervenarzt; 2003 Mar; 74 Suppl 1():S12-21. PubMed ID: 12624679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levodopa in the early treatment of Parkinson's disease.
    Murata M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapy of Parkinson disease. 1: Standard therapy of motor and non-motor symptoms].
    Kuhn W; Müller T
    Fortschr Neurol Psychiatr; 1997 Aug; 65(8):361-74. PubMed ID: 9378449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine receptor agonists in the treatment of advanced Parkinson's disease.
    Stocchi F
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S54-7. PubMed ID: 20123558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients.
    Rascol O; Lees AJ; Senard JM; Pirtosek Z; Brefel C; Montastruc JL; Fuell D
    Adv Neurol; 1996; 69():531-4. PubMed ID: 8615176
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease.
    Metman LV; Blanchet PJ; de Jong D; Mouradian MM; Chase TN
    Mov Disord; 1996 May; 11(3):257-60. PubMed ID: 8723141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
    Damier P; Tremblay L; Féger J; Hirsch EC
    Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Current preclinical findings on substances against Parkinson's disease].
    Gerlach M; Riederer P
    Nervenarzt; 2003 Mar; 74 Suppl 1():S2-6. PubMed ID: 12624677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
    Kondo T
    J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ropinirole in the symptomatic treatment of Parkinson's disease.
    Brooks DJ; Torjanski N; Burn DJ
    J Neural Transm Suppl; 1995; 45():231-8. PubMed ID: 8748630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Olanow CW; Obeso JA; Stocchi F
    Nat Clin Pract Neurol; 2006 Jul; 2(7):382-92. PubMed ID: 16932589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Arguments in favor of early treatment of Parkinson's disease with dopaminergic agonists].
    Rascol O
    Rev Neurol (Paris); 1999 Jan; 155(1):35-42. PubMed ID: 10093846
    [No Abstract]   [Full Text] [Related]  

  • 19. Maximizing the benefit:risk ratio of levodopa therapy in Parkinson's disease.
    Gottwald MD
    Pharmacotherapy; 1999 Nov; 19(11 Pt 2):162S-8S. PubMed ID: 10555944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pergolide: a useful agonist for the treatment of Parkinson disease].
    Bonnet AM; Houeto JL
    Rev Neurol (Paris); 2002 Jul; 158(6-7):744-5. PubMed ID: 12486908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.